Generic Name and Formulations:
Teriparatide (recombinant) 250mcg/mL; soln for SC inj; contains m-cresol.
Lilly, Eli and Company
Indications for FORTEO:
Postmenopausal osteoporosis in women who are at high risk for fracture. To increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. Treatment of men and women with osteoporosis associated with sustained glucocorticoid therapy at high risk for fracture (see literature).
20mcg SC once daily into thigh or abdominal wall; may treat for up to 2 years.
Potential risk of osteosarcoma.
Increased baseline risk for osteosarcoma (eg, Paget's disease of bone, unexplained increased alkaline phosphatase, open epiphyses, prior skeletal radiation therapy), bone metastases, history of skeletal malignancies, metabolic bone disease, hypercalcemia or risk thereof (eg, hyperparathyroidism): not recommended. Urolithiasis. Hypercalciuria. Hepatic, renal, or cardiac disease. Pregnancy (Cat.C). Nursing mothers: not recommended.
Hormone (human parathyroid hormone, recombinant).
Caution with digoxin (teriparatide-induced hypercalcemia increases risk of toxicity).
Arthralgia, pain, nausea; transient orthostatic hypotension, hypercalcemia, hyperuricemia, inj site reactions.
Multidose Pen (2.4mL)—1